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Sickle cell disease (SCD) is the most common inherited haemoglobin 
disorder.[1] This haemoglobinopathy is caused by a nucleotide base 
substitution (adenine – thymine) leading to an amino acid change 
from glutamic acid to valine on the beta-globin chain.[2] The amino 
acid substitution results in the formation of haemoglobin S (HbS), 
which has the potential of significantly reducing the lifespan of the red 
cell. In low oxygen tension environments HbS polymerises, causing 
elongation of the red cell, which takes on a ‘sickle’ shape. The normal 
red cell shape may be restored once an optimal oxygen environment 
returns, but after repeated episodes, the erythrocyte membrane 
becomes damaged and the sickle shape becomes irreversible.[3] The 
pathophysiology of SCD is complex, with patients suffering from 
a number of complications including vaso-occlusion and hypoxia 
leading to painful crises, increased infections, splenic dysfunction, 
haemolytic anaemia, aplastic crises and organ damage.[4]
While treatments such as hydroxyurea, gene therapy and stem cell 
transplantation have all been used with success, blood transfusion 
remains one of the most important forms of therapy.[5,6] The 
transfusion of blood products aids in restoring the number of normal 
red cells, improving oxygen-carrying capacity and blood flow, 
particularly during incidents of severe haemolysis.[7]
Although blood transfusions are an effective treatment for SCD, 
there are many risks including alloimmunisation, iron overload 
and transmission of blood-borne pathogens. The development of 
alloantibodies in the recipient, probably due to blood group antigenic 
differences between the donor and the recipient, can lead to delayed 
transfusion reactions that can be fatal.[8] Patients with SCD have 
been identified as having increased incidences of alloimmunisation 
despite full compatibility testing between donor and recipient. The 
most likely cause of this is the receipt of blood products from donors 
whose red cell antigens are phenotypically different to those of SCD 
patients, who are mainly of black African descent.[5]
Objectives
The incidence of SCD in South Africa (SA) has significantly increased 
as a result of migration and changing demographics. Consequently, 
the need for blood transfusions and blood products for this group 
of patients has escalated.[9] Cape Town has a diverse population, and 
as genetic disparity between donor and recipient is the most likely 
cause of alloantibody development, a study examining the rate of 
alloimmunisation in patients with SCD receiving blood products in 
Cape Town was considered important.
Our objectives were to analyse the frequency and distribution of 
red cell antibodies occurring in SCD patients who had received red 
blood cell products in Western Cape Province and to compare them 
with those in a group of non-SCD patients who had received a similar 
number of transfusions.
Methods
Study design and patient selection
This was a retrospective, cross-sectional study of 182 patients and 
controls who had received a minimum of one blood transfusion. 
Data from individuals receiving transfusions between 2010 and 2012 
were collected from the Western Province Blood Transfusion Service 
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(WPBTS). Information regarding age, clinical diagnosis, number 
of transfusions and antibodies was collected from the WPBTS’s 
Phoenix database and stored on an Excel spreadsheet, version 2010 
(Microsoft, USA). Patients who had required adult red blood cell 
concentrate, infant red blood cell concentrate, paediatric red blood 
cell concentrate, leucocyte-reduced red blood cell product or whole 
blood unit/s were included, while individuals both with and without 
SCD who had suffered from a recent viral or bacterial infection 
were excluded. The data from SCD patients were compared with 
those from a group of randomly selected non-SCD patients who had 
received a similar number of transfusions.
Ethical approval
Ethical approval was obtained from the Faculty of Health and Wellness 
Sciences Ethics Committee at the Cape Peninsula University of 
Technology (ref. no. CPUT/HW-REC 2016D1). Patient information 
was kept confidential and was anonymised by allocating a number to 
each patient and removing any personal information such as name, 
hospital number and identification number. Data collected were 
not shared with any unauthorised personnel and were stored on a 
password-protected computer that was only available to the principal 
investigator.
Data collection
Historical records of patients with ‘Sickle cell disease’ or ‘Sickle cell 
anaemia’ or ‘SCA’ or ‘SCD’ or ‘Hb SS’ or ‘Hb SC’ were collected. 
Information including patient age, blood group, antibodies and 
number of units issued was recorded on an Excel spreadsheet, version 
2010. Similar data were collected from a group of patients who had 
also received blood but did not have SCD. This control group was 
made up of randomly selected trauma, obstetric and leukaemia 
patients. As extended phenotyping was started in 2013, data were 
collected from 2010 to 2012 to avoid any bias and to reflect the true 
alloimmunisation rate of SCD patients before extended phenotyping 
began.
Blood grouping and antibody identification
ABO and Rh blood grouping as well as antibody screens were 
performed on the AutoVue or BioVue systems (Ortho Clinical 
Diagnostics, USA) using known cells or antisera supplied by Ortho 
Clinical Diagnostics. If antibody screens were positive, patient 
samples were sent to the WPBTS Reference Laboratory where the 
presence of any irregular antibodies was determined using a panel 
of 12 known-donor red blood cell suspensions to identify antibody 
or antibodies by a process of elimination. Each of the 12 donor cell 
suspensions was incubated with patient plasma, and if it was reactive 
with one of the cell suspensions expressing a particular antigen, 
the patient was identified as having developed an antibody to the 
corresponding antigen. If the reaction did not match the expected 
pattern of expression across the 12 donor cell suspensions, the 
antibody was referred to as unidentified. The presence of an antibody 
known to cause transfusion reactions and/or haemolytic disease of 
the fetus or newborn was considered clinically significant.
Statistical analysis
Data were recorded on an Excel spreadsheet, version 2010, and 
analysed using Statistica version 13 (Dell, USA). A p-value <0.05 
was considered significant when comparing the experimental group 
against the control data. The parameters were analysed for significance 
using descriptive analysis (means, ranges and frequencies), Student’s 
t-test and the χ2 test. Graphs and tables were created using Excel 2010.
Results
Patient demographics and blood groups
A total of 182 patients who had received at least one blood 
transfusion were studied. Of these, 91 (50%) had SCD. The other 
91 (50%) were trauma, obstetric and leukaemia patients who had 
received at least one blood transfusion but did not have SCD. 
The mean age of the SCD patient group was 20.9 years (range 4 - 
55), which was significantly lower than that of the control group 
(mean 45.2 years, range 7 - 94). Although the SCD patients had 
an increased incidence of alloimmunisation and development of 
clinically significant antibodies, this was not statistically different 
from the control group. The distribution of ABO blood group and 
Rh antigens was similar across the two groups, but patients with SCD 
had a significantly lower incidence of blood group A Rh positivity 
(p=0.047), The demographic data and blood group results are shown 
in Table 1.
Frequency of alloantibodies
The alloimmunisation rate with clinically significant antibodies 
was higher in the SCD patients (15.4%) than in the control group 
(9.9%), but this difference was not significant (p=0.172). Regardless 
of antibody type, 22.0% of the patient group and 13.2% of the control 
group became alloimmunised (p=0.119), with the median number 
of transfusions being higher in the control group (3.8) than in the 
patient group (2.8). However, a significantly increased number of 
total antibodies was detected in the SCD patients compared with 
the controls (p=0.016), and the number of unidentified antibodies 
present in the SCD group v. the controls was also significantly 
elevated (p<0.001) (Table 2).
Discussion
The objectives of this study were to document the frequency 
and distribution of allogeneic red cell antibodies in SCD patients 
receiving blood products in the Western Cape. Although the rate of 
alloimmunisation was similar to that of the controls (p=0.119), the 
results revealed significantly elevated numbers of total antibodies 
(p=0.016), of which many were unidentified (p<0.001).
Of the 91 SCD patients, 22.0% had been alloimmunised, and 
although this figure was not significantly different to that of the 
control group, it was higher than reported in many other studies 
in the literature, which range from 6.9% to 74%.[10-13] The rate of 
alloimmunisation is influenced by a number of factors including 
history of pregnancy, number of blood transfusions, age at first 
transfusion, sex and genetics.[5,14-16] In a study of SCD patients who 
had been fully cross-matched,[17] it was reported that individuals 
receiving more than 8.9 units of blood had a significantly higher 
alloimmunisation rate (59%) than those receiving less (15%). In our 
study, the median number of transfused units in SCD patients (2.77) 
was not significantly different to that in the control group (3.8), but 
the median age of the SCD patients was significantly lower (p<0.001). 
Many younger children have underdeveloped immune responses, 
and this may influence the recognition of foreign antigens and the 
consequent development of allogeneic antibodies.[18] Since their 
underdeveloped immune systems may not recognise donor antigens, 
it is therefore envisaged that as these children age and receive more 
transfusions, the rate of alloimmunisation will increase.
Despite the lower number of transfused units, the patients with SCD 
had a significantly increased number of total allogeneic antibodies 
(p=0.016), of which many were unidentified (p<0.001). These data 
must be interpreted in context, however, as although there was an 
increase in unidentified antibodies, the total number of clinically 
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significant alloantibodies in the two groups was not statistically 
different. Many of the detected antibodies were unidentified and had 
possibly developed to antigens not usually seen in our region.
SCD is prevalent throughout sub-Saharan Africa, the Middle 
East and India.[19] The majority of patients with SCD in Cape 
Town originate from Africa, in particular the Democratic Republic 
of the Congo.[9] One of the major causes of the development of 
allogeneic antibodies and alloimmunisation is the difference in the 
antigenic phenotype between the donor and the recipient.[5] In areas 
where there is ethnic diversity and the donor population is racially 
different to the recipients, the alloimmunisation rate is significantly 
increased.[20] This theory appears to be supported by other studies 
in countries with more homogeneous populations such as Uganda, 
where alloimmunisation rates are lower at 6%.[21]
According to the 2011 population census of the Western Cape,[22] 
the population had increased by 28% since the previous census in 
2001 and the increase was largely attributed to migration from other 
provinces and outside the country. The Western Cape has a total of 
5.8 million people, which can be broken down into those of mixed 
ancestry (48.8%), black Africans (32.8%), Asians (2%) and whites 
(15%). In contrast, although the WPBTS recruits donors across all 
ethnic groups residing in the Western Cape, the profile of donors is 
very different to the demographics of the province, and in particular 
those suffering from SCD. The WPBTS integrated report of 2017  - 
2018[23] indicated that 59% of donors were white, 34% of mixed 
ancestry, 1% Asian and 6% of black African descent. The increased 
number of unidentified antibodies may therefore be linked to 
antigenic differences resulting from the genetic and ethnic diversity 
in the region.
Patients with SCD have a number of additional factors that could 
predispose them to developing alloantibodies. These include clinical 
complications, an abnormal immune response, and polymorphisms 
of the immune regulatory gene TRIM21.[5,16] In addition, SCD has 
often been described as a chronic inflammatory disorder with 
increased inflammatory cytokines that could influence the rate of 
alloimmunisation and the development of autoantibodies.[24] In our 
Table 1. Patient and control group characteristics
Patients (N=91) Controls (N=91) p-value
Age (years), median (range) 20.9 (4 - 55) 45.2 (7 - 94) <0.001
Total units transfused 252 346 0.197
Mean* 2.77 3.8
Range* 1 - 17 1 - 45
Clinically significant antibodies, n (%) 14 (15.4) 8 (8.8) 0.172
Rate of alloimmunisation, n (%) 20 (22.0) 12 (13.2) 0.119
ABO and Rh, %
O positive 49.5 41.7 0.377
B positive 20.9 14.3 0.289
A positive 16.5 30.8 0.047
AB positive 3.3 4.4 0.705
Unidentified† 9.8 3.3 0.083
B negative 0 3.3 0.083
O negative 0 3.3 0.083
*Means and ranges of units transfused per patient.
†Patients who expressed blood group antigens not identified by the routine 12-donor red cell suspensions.
Table 2. Frequency of antibodies
Blood group system Alloantibody specificity
Number of alloantibodies
p-valueControl SCD
Rh D, E, e, C, c 2, 3, 0, 1, 1 0, 8, 1, 3, 1 D: 0.156
E: 0.121
e: 0.318
C: 0.314
c: 0.993
Kell K 2 3 0.652
MNSs S, s 1, 0 2, 1 S: 0.562
s: 0.318
Autoantibodies 4 6 0.517
Duffy Fyb 0 1 0.318
Other* 4 11 0.097
Unidentified 1 14 <0.001
Total antibodies 19 51 0.016
Clinically significant 14 26 0.162
SCD = sickle cell disease.
*Other antibodies detected in the SCD group were one each of anti-HI, Kpa, Xga, Lea, Leb, Lua, Cw and Rh34 and three anti-Ms. In the control group, one each of anti-HI, A1, f and Auto I were detected.
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study there was no difference in the development of autoantibodies 
between the two groups. Tests evaluating levels of inflammation were 
not available, so this association could not be made.
The result of alloimmunisation is the development of delayed 
haemolytic transfusion reactions due to the reaction of allogeneic 
antibodies to antigens expressed on the donor red cells. These 
antibodies are often not detected prior to the transfusion owing to 
low titres and lack of transfusion records. In addition, it is thought 
that the proinflammatory environment present in SCD promotes 
increased haemolysis of the donor cells and causes the patient’s 
sickled red cells to adhere to the vessel wall, causing vaso-occlusion. [5] 
These reactions can be life threatening and may be missed as they 
often occur up to 2 weeks after the transfusion has taken place. It 
is therefore important for clinicians to monitor patients who have 
received blood products carefully, and for blood transfusion services 
to implement strategies that attempt to prevent these reactions from 
occurring. These should include the transfusion of leucodepleted 
red cells and extended antibody screening. Recruitment of donors of 
black African descent and from population groups representative of 
patients with SCD is also required.
Study limitations
A limitation of this study was that full demographic and diagnostic 
information regarding the haemoglobin variant was not available. It 
is well recognised that certain haemoglobin variants are associated 
with increased alloimmunisation rates. For example, individuals with 
the homozygous HbSS and HbSb0 thalassaemia variants have higher 
incidences of alloimmunisation than those with HbSC.[25] In Cape 
Town, HbC and thalassaemia have been identified in individuals of 
mixed ancestry and in those of Indian and Mediterranean descent.[9] 
In order to understand the above findings fully, further studies would 
therefore need to include full demographic and diagnostic criteria.
Conclusions
Despite the above limitation, this study has been able to conclude 
that patients with SCD develop significantly elevated numbers of 
allogeneic antibodies, of which many are unidentified. The disparity 
between donor and patient red cell phenotypes is the most likely 
cause. The Western Cape has many diverse population groups, and 
as migration from other parts of the African continent is likely to 
continue, the incidence of diseases such as SCD will continue to rise. 
The blood transfusion services throughout SA have an important 
role to play in the treatment and survival of these patients, and will 
therefore be required to address these challenges. New strategies 
to recruit donors from all population groups, including those from 
Central Africa, and more comprehensive antibody screening may be 
required.
Since completion of this study, extended phenotyping for SCD 
has been introduced and further research investigating the impact of 
these strategies is under way.
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